According to our recent payer coverage analysis for Duchenne muscular dystrophy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for Duchenne muscular dystrophy treatments shows that under the pharmacy benefit, about 35% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In February 2021, the FDA gave accelerated approval to Sarepta Therapeutics, Inc.’s Amondys 45 (casimersen) for the treatment of Duchenne muscular dystrophy in people with a confirmed mutation amenable to exon 45 skipping.